BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2018

Mar 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2018-03-15

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-15	Common Stock	M	15000	$38.59	Acquired	279674	Direct
2018-03-15	Common Stock	S	15000	$84.7267	Disposed	264674	Direct
2018-03-15	Common Stock	F	14908	$83.57	Disposed	249766	Direct
2018-03-15	Common Stock	A	46340	—	Acquired	296106	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-15	Stock Option (Right to buy Common Stock)	$38.59	M	15000	Acquired	2018-05-21	Common Stock (15000)	Direct
2018-03-15	Stock Option (Right to buy Common Stock)	$83.57	A	148190	Acquired	2028-03-14	Common Stock (148190)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	182201	Indirect

Footnotes

F1: This transaction, originally due to be reported on Monday, March 19, 2018, is being reported late due to an administrative oversight.

F2: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.

F3: The price in column 4 is the weighted average price. The price actually received ranged from $84.26 to $85.91. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F4: Restricted stock units granted on March 15, 2018. Price not applicable.

F5: Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter.